Kailera Therapeutics KLRA
NASDAQ KLRA
$13.27 +0.06 (+0.45%)
At close: Nov 13, 2026 · 4:00 PM EST

Kailera Therapeutics (KLRA) EBIT (2025 - 2026)

Updated

Kailera Therapeutics (KLRA) recorded EBIT of -$106.34 million in Q3 2026, compared with -$40.11 million a year earlier.

Analysis

Kailera Therapeutics (KLRA) EBIT (2025 - 2026) Analysis & Trends

On a TTM basis, Kailera Therapeutics' EBIT came in at -$379.49 million as of Sep 30, 2026; for FY2025, it came in at -$158.34 million.

  • Across earlier years, EBIT came in at -$230.42 million in FY2024.
  • Quarterly EBIT has ranged from -$121.37 million in Q2 2026 to -$20.46 million in Q1 2025 over the past five years.
  • Per Business Quant, the preceding three quarters came in at -$121.37 million (Q2 2026), -$84.66 million (Q1 2026) and -$67.12 million (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn 8.41 Bn
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn 6.18 Bn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn 6.27 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn 5.56 Bn
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn 4.39 Bn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn 3.71 Bn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn 3.46 Bn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn 5.47 Bn
10 Kailera Therapeutics 1.72 Bn -1.16 Bn - -106.34 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -106.34 Mn
Jun 30, 2026 -121.37 Mn
Mar 31, 2026 -84.66 Mn
Dec 31, 2025 -67.12 Mn
Sep 30, 2025 -40.11 Mn
Jun 30, 2025 -30.65 Mn
Mar 31, 2025 -20.46 Mn
API Access

Kailera Therapeutics EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit&ticker=KLRA&period=max&api_key=YOUR_API_KEY